Intermountain has developed waveform analysis software for Left Ventricular Assist Devices (LVAD) that can determine whether the aortic valve is opening and closing in a synchronous fashion with the use of the LVAD, based on a large historical set of patient data from Intermountain's extensive electronic medical records database. The software can potentially be integrated into most LVADs, and can adjust the LVAD when it is not performing optimally. The method utilizes electrical current analysis as a means to provide feedback to the LVAD device regarding valve synchronization and potentially can provide a means to auto-correct the LVAD. This tool could be used on an intermittent basis to monitor LVAD quality, or on a real-time continuous basis with a feedback alert. This invention could eliminate repeat echocardiograms and in-hospital LVAD adjustments, which is currently the best available practice. In the US, 5.8M people have been diagnosed with heart failure (HF), with 670,000 new cases diagnosed every year. For people diagnosed with HF, the prognosis is poor, with 50% mortality within 5 years. HF diagnosis and treatment cost the US $34.4B in 2011. For patients in late-stage HF, heart transplantation is the only curative treatment, but there are not nearly as many available hearts as there are HF patients. Many of these late-stage HF patients receive a ventricular assist device (VAD) to provide additional support to their weakened hearts. The patients fall into four categories: 1) bridge to decision; 2) bridge to transplant; 3) bridge to recovery, and: 4) destination therapy. The VAD is designed to assist a weak heart, moving blood under pressure from a pre-valve access point to a post-valve re-entry point. Blood flow must be matched to the natural opening and closing and pressure of the patient's heart. The standard method of determining whether the aortic valve is opening and closing optimally is by subjecting the patient to an echocardiogram, an expensive in-hospital procedure. Intermountain's LVAD Waveform Analysis Algorithm software can potentially eliminate the need for repeated echocardiograms. LVADs comprise 73% of the global market, while right ventricular assist devices (RVADs) and bi-VADs (left and right pumps), make up the remaining 27%. Currently, the US VAD market is $391M, growing at 13%, while the worldwide market is $616M, growing at 11%. Intermountain Healthcare's LVAD Waveform Analysis Algorithm could improve LVAD performance, reduce costs, and improve the quality of care for patients in late-stage HF. A patent application is pending (US 20100087742), supporting research and a publication is available, and an initial prototype is being developed. Intermountain Healthcare is looking for a commercial partner to develop and commercialize this concept. For further information, contact Ahsen Khan at 801-408-5360, ahsen.khan@imail.org.